Advertisements

Percocet 5/325

Quick links to important sections

Percocet 5/325

Advertisements
Advertisements

Treatment option: Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Percocet 5/325

Quick Facts

Property Description
Active Ingredients Oxycodone Hydrochloride, Acetaminophen
Form Oral Tablet (Immediate-Release)
Pharmacological Class Combination Analgesic (Opioid and Non-Opioid)
General Purpose Relief of moderate to severe pain
Origin Synthetic Opioid Derivative and Synthetic Non-Opioid Compound

What is Percocet 5/325 and How is it Classified?

Percocet 5/325 is a prescription-only, oral tablet classified as a fixed-dose combination (FDC) analgesic. This medication contains two distinct active substances: the opioid compound Oxycodone Hydrochloride and the non-opioid compound Acetaminophen (Paracetamol). The combination of these two ingredients defines its identity, and the specific 5 mg to 325 mg ratio distinguishes this particular formulation.

The Oxycodone component, a semisynthetic opioid derivative, is subject to regulatory control due to its analgesic properties and is designated as a controlled substance. The FDC structure is characteristic of this drug, differentiating it from single-agent products. This formulation is designed as an immediate-release tablet, intended for rapid systemic absorption after oral administration, which is a key factor in its use profile.

The Dual Nature of Percocet 5/325: Opioid and Non-Opioid Composition

The core function of Percocet 5/325 relies on the combined action of its two distinct pharmacological classes. The Oxycodone acts on the central nervous system to modify the perception of pain, while the Acetaminophen component contributes to overall pain relief through separate, non-opioid mechanisms. The combination of these two agents is intended to realize a synergistic action, thereby allowing for an opioid-sparing effect.

General Purpose: What Kind of Discomfort Does it Address?

The primary therapeutic goal of this fixed combination medication is the relief of moderate to severe pain. The medication is utilized when a healthcare professional determines that the patient's discomfort requires the simultaneous and fixed-ratio action of both an opioid and a non-opioid agent for appropriate management. This dual-action approach is reserved for situations where single-agent non-opioid treatments are deemed insufficient.

Advertisements

What side effects are possible with Percocet 5/325?

Possible Side Effects and Safety Information

The official safety profile for this combination medication is structured around the distinct risks of its two active components, Oxycodone and Acetaminophen, as documented in government regulatory labeling. The adverse reactions are classified by frequency and the body system affected.

Documented Adverse Reactions and Frequencies

Adverse reactions are grouped based on the documented incidence found in clinical experience and post-marketing surveillance. The most frequently observed, generally non-serious reactions include lightheadedness, dizziness, drowsiness (somnolence), nausea, and vomiting. Reactions officially categorized as common (incidence geq 5%) also include constipation, pruritus (itching), headache, dry mouth, and sweating.

System-Organ Class Examples of Documented Effects
Nervous System Sedation, dizziness, euphoria, dysphoria.
Gastrointestinal Constipation, nausea, vomiting.
Skin & Subcutaneous Tissue Pruritus, skin eruptions.

Serious Adverse Reactions and Safety Constraints

The regulatory label documents the potential for serious, life-threatening events. These include Respiratory Depression, which carries the highest risk during the initiation of treatment or following a dosage increase, and Acute Liver Failure (Hepatotoxicity), which is associated with the Acetaminophen component and can be dose-dependent. The potential for Circulatory Depression and severe Hypersensitivity Reactions is also officially noted.

Safety considerations apply to specific populations. Elderly patients are documented as being at greater risk for respiratory depression. Additionally, extended maternal use during pregnancy is linked to the risk of Neonatal Opioid Withdrawal Syndrome in the newborn. The use of this medication is explicitly restricted in individuals with known hypersensitivity to its components and requires caution in those with pre-existing conditions like severe respiratory impairment.

Advertisements

Overdose and Emergency Response

An overdose of Percocet 5/325 involves the distinct toxic effects of both the Oxycodone and Acetaminophen components, defining a dual-toxicity profile.

The officially documented manifestations of an opioid overdose include life-threatening respiratory depression (slowed or shallow breathing), extreme somnolence that may progress to stupor or coma, pinpoint pupils, and cyanosis. These severe signs can rapidly lead to circulatory collapse and cardiac arrest. The respiratory depressant effects are noted in official labeling to be markedly exaggerated in the presence of head injury.

The acetaminophen component presents an immediate risk of early symptoms like nausea, vomiting, and diaphoresis, but the critical, delayed outcome is potentially fatal hepatic necrosis and acute liver failure, which may not be clinically apparent until 48 to 72 hours post-ingestion.

Seek immediate medical attention for any suspected overdose or accidental ingestion, as regulatory agencies define these scenarios as potentially life-threatening emergencies. The mandated emergency response includes securing a patent airway and instituting controlled ventilation. Specific antidotes are documented: Naloxone to reverse opioid-induced respiratory depression and N-acetylcysteine for acetaminophen toxicity. Hospital monitoring requires obtaining a serum acetaminophen assay and repeating liver function studies at 24-hour intervals.

Advertisements

Therapeutic Uses of Percocet 5/325

What Percocet 5/325 Treats: Main Uses and Benefits

Percocet 5/325 is commonly used for the management of moderate to severe pain, relevant in contexts where additional management of discomfort is required beyond that provided by non-opioid medications. Its dual composition is applied across domains where additional symptomatic support is needed, particularly when symptoms may intensify temporarily.


Relief for High-Intensity Symptoms

This combination medication is applied in situations involving significant symptomatic discomfort, typically when pain is classified as moderate, moderately severe, or severe. It is commonly used for acute, time-limited episodes such as postoperative pain following surgical procedures, pain arising from acute traumatic injuries, or intense dental pain.

“This combined analgesic is relevant for managing symptoms that interfere with daily comfort and may assist with maintaining functional stability during challenging episodes.”

It provides support that helps ease the overall symptom burden, contributes to improved day-to-day comfort, and may assist with maintaining functional stability. Furthermore, its application extends to providing symptomatic assistance for breakthrough pain—sudden, intense flares—and contributing to easing fever symptoms, which may assist with maintaining a sense of stability during periods of heightened symptoms.


Quick Fact: Symptom Domain Description
Pain Severity Targeted Moderate, Moderately Severe, and Severe pain
Common Clinical Contexts Post-operative recovery and Acute traumatic injuries
Dual Symptom Relief Pain reduction and assistance with fever symptoms
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Percocet 5/325 (oxycodone and acetaminophen) is strictly reserved for adult patients (18 years and older) who do not present with specific contraindications or risk factors, as documented in official government labeling. The eligibility profile is defined by both absolute prohibitions and conditional restrictions related to physiological status and specific comorbidities.

Absolute Contraindications (Must Not Use)

  • Known hypersensitivity to oxycodone, acetaminophen, or any inactive component.
  • The presence of significant respiratory depression, acute or severe bronchial asthma, or paralytic ileus (known or suspected gastrointestinal obstruction).

Population-Specific Limitations

Population Group Regulatory Status
Pediatric Patients Safety and effectiveness have not been established.
Hepatic/Renal Impairment Use with Caution due to altered clearance and potential hepatotoxicity.
Pregnancy (Prolonged Use) Not recommended; associated with risk of Neonatal Opioid Withdrawal Syndrome (NOWS).
Lactation Not recommended due to risk of infant sedation and respiratory depression.
Geriatric Patients Use with Caution; increased risk for respiratory depression.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication contains both oxycodone (an opioid) and acetaminophen. The official interaction profile primarily focuses on risks associated with oxycodone, including the potential for severe central nervous system (CNS) depression and Serotonin Syndrome.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Categories/Substances
Additive CNS/Respiratory Depression Other opioids, General Anesthetics, Benzodiazepines, Other Sedative-Hypnotics, Phenothiazines, Alcohol
Increased Oxycodone Exposure CYP3A4 Inhibitors (e.g., macrolide antibiotics, azole-antifungals)
Decreased Oxycodone Exposure CYP3A4 Inducers (e.g., rifampin, phenytoin)
Serotonin Syndrome Risk Serotonergic Drugs (e.g., SSRIs, SNRIs, tricyclic antidepressants)
Increased Risk of Paralytic Ileus Anticholinergics

Regulatory Constraints and Monitoring

The co-administration of this medicine with benzodiazepines or other CNS depressants carries a regulatory warning due to the risk of profound sedation, respiratory depression, coma, and death; this combination is generally discouraged unless alternatives are inadequate. Concomitant use with CYP3A4 inhibitors requires close monitoring for signs of increased opioid effects (e.g., respiratory depression), and use with CYP3A4 inducers requires monitoring for reduced analgesic effect or withdrawal symptoms. When combined with serotonergic drugs, careful observation is required, especially during treatment initiation and dosage changes, due to the risk of Serotonin Syndrome.

Advertisements

Mechanism of Action

How Percocet 5/325 Works

Percocet 5/325 operates via the distinct actions of its two components, focusing primarily on the central nervous system (CNS).

Central Sensory Signaling Modulation

The Oxycodone component functions as an agonist, directly binding to and activating mathbfmu -opioid receptors located on nerve cells in the brain and spinal cord. This interaction interferes with neurotransmitter processes responsible for mathbftransmitting and processing sensory signals in the CNS, resulting in an altered central processing of these signals.

Central Enzyme Inhibition and Thermoregulation

The Acetaminophen component works primarily in the CNS by mathbfinhibiting specific cyclooxygenase (COX) enzymes. This mathbfreduces the synthesis of prostaglandins, which are chemical mediators. Limiting prostaglandin synthesis within the brain influences the thermal set-point established by the mathbfhypothalamus, thus influencing central thermoregulatory control.

Dual Pathway Convergence

The drug's systemic action results from the mathbfconvergence of these two separate mechanisms: mathbfreceptor agonism and mathbfenzyme inhibition. By acting upon distinct pathways, the two components mathbfaugment the central modulation of both signal transmission and mediator levels. The combined action results in an altered neural signaling and central regulation of body temperature.

Advertisements

Dosage and Administration Information

Official Administration Protocol

Percocet is an immediate-release tablet indicated for administration via the oral route only. This formulation is utilized for the short-term management of acute pain.

Dosing and Frequency

The standard adult starting dose is typically one or two tablets (5 mg Oxycodone / 325 mg Acetaminophen strength) taken every 6 hours as needed (PRN) for pain. This as-needed frequency maintains a minimum interval of 6 hours between doses.

A critical constraint on administration is the total daily intake of Acetaminophen from all sources, which must not exceed 4,000 mg per day.

Administration Scope Administration Details
Route of Administration Oral (tablet swallowed whole)
Initial Adult Dose One or two 5 mg/325 mg tablets
Frequency Pattern As needed (PRN), every 6 hours
Food Relationship May be taken with or without food

Handling and Population-Specific Rules

Administration of the tablet typically involves it being swallowed whole; the tablets are not to be crushed, broken, or dissolved.

For older adults (geriatric patients) and individuals with hepatic or renal impairment, caution is warranted due to potential increased sensitivity or altered drug metabolism. If the medication has been administered for an extended duration, discontinuation is achieved by gradual dose reduction (tapering).

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Percocet 5/325

Evidence for use in Acute Pain (Moderate to Moderately Severe)

The primary research for the oxycodone/acetaminophen combination was studied for conditions involving time-limited, often intense pain. Research examined the use of this medication during periods of increased symptom activity following procedures like dental extractions or minor surgeries, primarily using short-term Randomized Controlled Trials (RCTs) which compared the combination against a placebo, acetaminophen alone, or other pain relievers.

Studies monitored outcomes related to physical discomfort. Specifically, researchers used standardized scales to measure pain intensity and observed how symptoms evolved in the observed populations during the hours immediately following the intervention. Research highlights changes measured during the study period, focusing on the time intervals over which patients reported changes and the pattern of patient usage of rescue medication. Findings describe patterns observed in the studies.

Follow-up durations were limited, often covering only the first few hours or days after the pain episode began. The existing body of evidence is primarily derived from RCTs and is descriptive of immediate symptom patterns in these controlled settings, but results apply only to the specific populations studied during these defined time intervals.

Evidence for use in Chronic Pain (Moderate to Severe)

The medication was also studied for conditions characterized by functional limitations and where symptoms may vary in intensity, such as chronic low back pain. Research examined the combination in conditions where symptoms presented functional limitations, with this area explored using systematic reviews, a limited number of randomized trials, and prospective studies.

Studies monitored outcomes related to functional imbalance. Research examined patient-reported outcomes describing perceived discomfort, changes in pain intensity, and how the pain interfered with a patient's daily functioning or activity level. Findings help contextualize how patients reported their experience during the defined research scenarios.

The findings were mixed across studies, and data on sustained outcomes are still emerging. The immediate-release formulation was evaluated in studies conducted during periods of increased symptom activity, but findings describe group patterns, not personal outcomes over the long term.

Long-term Studies and Follow-up

The overall body of evidence for the immediate-release formulation centers on short-term or episodic symptom patterns. Follow-up durations were limited across most of the core research. For the acute pain contexts, evidence provides limited insight into outcomes beyond the initial week of use.

For conditions involving periods of heightened symptoms, like chronic pain, the study periods were typically short relative to the nature of the condition, often lasting only four weeks. There is limited information for long-term outcomes, and the long-term effects are not fully established. Research provides insight into short-term changes, but the long-term patterns and durability of effects have not been fully established through controlled studies lasting a year or more.

Evidence in Special Populations

Research has explored the use of the combination in special populations, particularly older adults. Findings in these groups are typically derived from subgroup analyses of the main trials, meaning sample sizes were modest for these specific populations.

Data for children and adolescents remain insufficient. The evidence base has not fully characterized the observed outcomes for this medication in pediatric populations. Research does not determine whether an individual will respond similarly across all age groups, highlighting that results apply only to the populations studied.

What is still uncertain about Percocet 5/325 Evidence

The evidence highlights what is known—and what is still uncertain. The primary uncertainty relates to the long-term outcomes and durability of measured changes, as follow-up durations were limited across the core studies. Data for certain groups, particularly pediatric patients, remain insufficient.

Studies monitored outcomes related to the combination when compared against a placebo, while results varied when compared to other specific analgesic regimens. Subgroup findings across different pain types and specific comorbidities are often uncertain or have limited information.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Percocet 5/325 (FAQ)


Q: How quickly does Percocet typically start working after it is taken?

According to official product information, this is an immediate-release tablet designed for quick systemic absorption. The medication is formulated to begin working rapidly after it is taken orally.


Q: How long does the pain-relieving effect of Percocet 5/325 generally last?

Studies and official information indicate that the pain-relieving effect of the immediate-release formulation typically lasts for about four to six hours. This duration aligns with the recommended interval for taking the medication as needed for acute pain management.


Q: Does the body become used to Percocet if it is taken for a long period?

Official warnings state that repeated use, even as prescribed, can lead to the body developing tolerance and physical dependence. Physical dependence is a normal physiological adaptation that makes the body rely on the drug’s presence. If use is prolonged, the official use protocol describes gradual dose reduction (tapering) as a necessary procedure if the drug is discontinued.


Q: Why is there a specific warning about the maximum daily amount of acetaminophen in Percocet?

The official product information carries a strict warning about the maximum daily intake of acetaminophen from all sources. This limit is critical because exceeding the recommended amount is associated with a high risk of causing serious or potentially fatal acute liver failure, which is also called hepatotoxicity.


Q: What research evidence exists regarding the pain management use of Percocet 5/325?

The primary evidence supporting the use of this medication comes from short-term Randomized Controlled Trials, which examined its effects in acute, time-limited pain. The available evidence provides limited insight into long-term outcomes. Furthermore, official information indicates that data for pediatric populations is insufficient to characterize observed outcomes.


Q: Why is Percocet classified as a Schedule II controlled substance?

Percocet is classified as a Schedule II controlled substance by government authorities because its oxycodone component is an opioid compound. Schedule II classification is reserved for substances with a high potential for abuse, which may lead to severe physical or psychological dependence.


Q: How long does it typically take for Percocet to be fully eliminated from the system?

The elimination time is determined by the half-lives of the two components. Oxycodone has a half-life of approximately 3.5 to 5.5 hours, and acetaminophen has a half-life of 2 to 3 hours. It generally takes several of these half-life periods for the drug's components to be substantially eliminated from the body.


Q: Why do some users report a feeling of itching or nausea after taking an opioid-containing medicine?

Official product documents note that common side effects like nausea, vomiting, and itching (pruritus) are linked to the effects of the opioid component. Opioids can affect the central nervous system and influence smooth muscle tone in the gastrointestinal tract, or potentially trigger histamine release, which can lead to these reported feelings.


Q: What is the difference between opioid tolerance and opioid physical dependence?

Tolerance is a condition where the body adapts to the medication, meaning a greater amount is required to achieve the same effect. Physical dependence, however, is a physiological adaptation in which the body needs the drug's presence to prevent withdrawal symptoms from occurring. Both are potential outcomes of repeated opioid use, as documented in official information.


Q: What signs should a person be aware of that might indicate a serious side effect?

Official safety guides describe key indications of severe respiratory depression, such as unusually shallow breathing or difficulty being awakened from sleep. They also describe signs of potential liver damage, such as yellowing of the skin or eyes, or pain in the upper right abdomen.


Q: Are food or drink restrictions mentioned in the official information for Percocet?

While the official administration protocol indicates the tablet may be taken with or without food, information in the regulatory documents suggests caution with certain products. Specifically, consuming grapefruit products is noted to potentially alter the body's processing of the drug and increase the level of oxycodone in the system.


Q: Can non-prescription or herbal supplements interact with Percocet?

Yes, official warnings advise caution regarding the use of non-prescription and herbal supplements. Certain supplements, such as St. John's Wort, are noted to potentially affect the drug's metabolism. Additionally, any herbal supplement with sedative properties may increase the risk of drowsiness when combined with Percocet.


Q: How does Percocet compare to Tylenol with codeine (e.g., in terms of opioid strength)?

Percocet contains the opioid oxycodone, while Tylenol with Codeine contains the opioid codeine. Official indications for Percocet reserve its use for moderate to severe pain, whereas codeine-containing products are typically reserved for pain of a different severity. Both medications are classified as controlled substances by regulatory bodies.


Q: Are there official recommendations for the proper storage and disposal of unused Percocet tablets?

Official documents describe that unused tablets should be stored securely away from children and pets. The preferred method for disposing of unused or expired controlled substances is through a DEA-registered drug take-back program. If a program is not immediately available, the FDA specifies flushing the tablets down the toilet as an acceptable alternative for this medication to prevent accidental exposure.


Q: What does 'off-label use' mean in the context of prescription medicines like Percocet?

The term 'off-label use' refers to the practice of prescribing a medication for a condition, dose, or patient population that has not been specifically reviewed and approved by the regulatory agency. This means the use is outside the scope of the drug’s official labeling and indications.


Q: Can other common painkillers interact with Percocet?

Yes, caution is advised regarding the use of other common painkillers. Official information advises caution when combining Percocet with certain non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin. This is because the combination may be associated with an increased risk of certain gastrointestinal side effects.


Q: Are there known interactions between Percocet and common over-the-counter medicines?

Yes, there are documented interactions between Percocet and several common over-the-counter (OTC) medicines. The official regulatory warning highlights the need to avoid all other medicines that contain acetaminophen due to the risk of liver damage. Additionally, OTC medicines that cause drowsiness, such as certain cold or sleep aids, may increase the risk of sedation when combined with Percocet.

Advertisements

How should Percocet 5/325 be stored and disposed of?

How to Store and Dispose of Percocet 5/325

Storage Requirements

Percocet (oxycodone and acetaminophen) tablets should be stored securely and safely away from the sight and reach of children and pets. This secure location should not be accessible to others, including visitors, to prevent accidental ingestion, misuse, or theft. For stability, the medication should be dispensed and stored in a tight, light-resistant container as defined by the United States Pharmacopeia (USP).

Disposal Instructions

Percocet is a Schedule II controlled substance. The preferred method for disposal is a drug take-back program, such as a DEA-registered collection site or a community medicine take-back event. If a take-back option is not immediately available, expired, unwanted, or unused medication should be disposed of by flushing it down the toilet. This is a designated method for certain controlled substances like Percocet to reduce the risk of accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Percocet 5/325 found in:

A-Z Index: